Meglumine Sodium Succinate

Phase 2Small molecule

PPOLYSAN Scientific & Technological Pharmaceutical Company

Meglumine Sodium Succinate is one of 5 small molecule programs targeting Metabolic Acidosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic AcidosisActive, not recruiting

Metabolic AcidosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Metabolic Acidosis

#DrugCompanyPhaseTrials

Alka-Seltzer

AAbbott

Phase 3

1 2

Klor-Con

Novartis

Phase 2

1 3

Potassium Iodide

DDawnrays Pharmaceutical (Holdings) Limited

Phase 2

1 4

Veverimer

RRenibus Therapeutics, Inc.

Phase 3

—5

Meglumine Sodium Succinate

PPOLYSAN Scientific & Technological Pharmaceutical Company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metabolic Acidosis1 trial

Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients

Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 2·NCT05147051·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Meglumine Sodium Succinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meglumine Sodium Succinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meglumine Sodium Succinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — POLYSAN Scientific & Technological Pharmaceutical Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPOLYSAN Scientific & Technological Pharmaceutical Company

Meglumine Sodium Succinate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metabolic Acidosis1 trial

References

Drug Info

Quick Facts

Related News